Navigation Links
Clostridium difficile Infection: Current Challenges and Controversies
Date:1/20/2009

Complimentary Continuing Education Virtual Lecture and Podcast for Healthcare Professionals

VOORHEES, N.J., Jan. 20 /PRNewswire/ -- Current education about Clostridium difficile infection (CDI) is critical for several reasons. The epidemiology of CDI is changing and has been marked by increasing rates and more severe disease. In addition, the epidemic strain continues to be reported in an expanding list of states across the United States and worldwide.

To address the need for current education on CDI risk factors, diagnostic techniques, and optimal treatment strategies, Robert Michael Educational Institute LLC (RMEI) and Postgraduate Institute for Medicine (PIM) are jointly sponsoring a complimentary continuing education virtual lecture and podcast for physicians, pharmacists, and nurses titled Clostridium difficile Infection: Current Challenges and Controversies. This activity is supported by an educational grant from ViroPharma Incorporated.

The information contained in this virtual lecture and podcast was originally presented as a live symposium during the 2008 ICAAC/IDSA Joint Meeting. The chairperson for this program is international expert in infectious diseases, Dale N. Gerding, MD, FACP, FIDSA, Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois, and Associate Chief of Staff for Research and Development at Hines Veterans Affairs Hospital in Hines, Illinois. Other faculty include experts in infectious diseases, gastroenterology, and infection control from leading medical institutions across the United States.

Healthcare professionals can visit www.rmei.com/CDI052 to access this virtual lecture and podcast.

"Robert Michael Educational Institute LLC recognizes that continuing education plays a crucial role in the provision of quality healthcare and is dedicated to offering professionals meaningful opportunities for lifelong learning," says President and CEO, Robert M. Colleluori.

RMEI is a medical education company that specializes in independent, accredited, and nonaccredited education. The goal of all accredited RMEI educational offerings is to promote a spirit of lifelong learning and continuous professional development. RMEI works closely with medical experts to design activities that improve diagnosis and treatment. These activities include national and international symposia, teleconferences, live meetings, enduring print materials, and interactive Internet programs.

For other educational opportunities, please visit www.rmei.com.


'/>"/>
SOURCE Robert Michael Educational Institute LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
2. Putting a new spin on current research
3. New small-scale generator produces alternating current by stretching zinc oxide wires
4. Solos Endoscopy, Inc. in Final Stages to Upgrade Pink Sheet Status from Limited to Current Information
5. Huifeng Bio-Pharmaceutical (HFGB) Provides Update on Current Business and COS Certification
6. 72% of Women Are Dissatisfied With Their Current Treatment of Vaginal Infection, Survey Finds
7. Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer
8. Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
9. National Stem Cell Holding, Inc. Has Engaged BMA Securities to Assist and Advise the Company With Its Current Capital Raise of $3,500,000
10. GlaxoSmithKline Consumer Healthcare Recommends Maintaining FDAS Current Two-Class Drug System
11. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the second ... a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, ... from US2020. , US2020’s mission is to change the trajectory of STEM education ...
(Date:10/10/2017)... Oct. 10, 2017 SomaGenics announced the receipt ... to develop RealSeq®-SC (Single Cell), expected to be the ... RNAs (including microRNAs) from single cells using NGS methods. ... need to accelerate development of approaches to analyze the ... "New techniques for measuring levels of mRNAs in ...
Breaking Biology Technology:
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
Breaking Biology News(10 mins):